Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 17-24

  Xu, Wen Ting ^a   Yang, Zhen ^a   Lu, Nong Hua ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Chemoresistance; Gastric cancer; Gene therapy; Inactivation; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

DRUG RESISTANCE; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STOMACH TUMOR;

DRUG RESISTANCE, NEOPLASM; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894051794     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.17     Document Type: Review

References (89)

1. Baig RM, Mahjabeen I, Sabir M, et al (2011). Genetic Changes in the PTEN Gene and their Association with Breast Cancer in Pakistan. Asian Pacific J Cancer Prev, 12, 2773-8.
2. Bai ZG, Ye YJ, Shen DH, et al (2013). PTEN expression and suppression of proliferation are associated with Cdx2 overexpression in gastric cancercells. Int J Oncol, 42, 1682-91.
3. Besson A, Robbins SM, Yong VW(1999). PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem, 263, 605-11.
4. Byun DS, Cho K, Ryu BK, et al (2003). Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK-3CA amplification in gastric carcinoma. Int J Cancer, 104, 318-27.
5. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67-73.
6. Carson JP, Kulik G, Weber MJ (1999). Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B. Cancer Res, 59, 1449-53.
7. Chang JG, Chen YJ, Perng LI, et al (1999). Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer, 35, 647-51.
8. Cheung HH, Davis AJ, Lee TL, et al (2011). Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene, 30, 3404-15.
9. Chong ML, Loh M, Thakkar B, et al (2013). Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation. Int J Cancer, 134, 1232-8.
10. Chun-Zhi Z, Lei H, An-Ling Z, et al (2010). MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer, 10, 367.
11. Ciuffreda L, Di Sanza C, Cesta Incani U, et al (2012). The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl), 90, 667-79.
12. Cox G, O'Byrne KJ (2001). Matrix metalloproteinases and cancer. Anticancer Res, 21, 4207-19.
13. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378, 785-9.
14. Datta SR, Dudek H, Tao X, et al (1997). Akt phosphorylation of Bad couples survival Signals to the cell-intrinsic death machinery. Cell, 91, 231-41.
15. Deng N, Goh LK, Wang H, et al (2012). A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 61, 673-84.
16. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998). Gl ycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular lvocalization. Genes & Development, 12, 3499-511.
17. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab responseand survival in patients with HER2-positive metastatic breast cancer. Am J Pathol, 177, 1647-56.
18. Gericke A, Munson M, Ross AH (2006). Regulation of the PTEN phosphatase. Gene, 374, 1-9.
19. Guggenheim DE, Shah MA (2013). Gastric cancer epidemiology and risk factors. J Surg Oncol, 107, 230-6.
20. Gu J, Tamura M, Yamada KM (1998). Tumor Suppressor PTEN inhibits integrin-and Growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol, 143, 1375-83.
21. Guo J, Miao Y, Xiao B, et al (2009). Differential expression of microRNA species in human gastric cancer versus non-tumorous Tissues. J Gastroenterol Hepatol, 24, 652-7.
22. Gyenge M, Amagase K, Kunimi S, Matsuoka R, Takeuchi K (2013). Roles of pro-angiogenic and anti-angiogenic factors as well as matrix metalloproteinases in healing of NSAID-induced small intestinal ulcers in rats. Life Sci, 93, 441-7.
23. Hang Y, Zheng YC, Cao Y, Li QS, Sui YJ (2005). Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol, 11, 2224-9.
24. He RF, Hu ZL, Wen JF (2007). Biological implication of PTEN gene expression in human gastric cancer and related molecular mechanisms. Zhonghua Binglixue Zazhi, 36, 324-8.
25. Hino R, Uozaki H, Murakami N, et al (2009). Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res, 69, 2766-74.
26. Hobert O (2008). Gene regulation by transcription factors and microRNAs. Science, 319, 1785-6.
27. Huang J, Kontos CD (2002). PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem, 277, 10760-6.
28. Hwang PH, Kim SY, Lee JC, et al (2005). PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells. Exp Mol Med, 37, 391-8.
29. Hwang PH, Yi HK, Kim DS, et al (2001). Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett, 172, 83-91.
30. Jemal A, Bray F, Center MM, et al (2011). Global cancer Statistics. CA Cancer J Clin, 61, 69-90.
31. Kang YH, Lee HS, Kim WH (2002). Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest, 82, 285-91.
32. Kim JH, Kang JW, Kim MS, et al (2012). The apoptotic effects of the flavonoid N101-2 in human cervical cancer cells. Toxicol In Vitro, 26, 67-73.
33. Kim JS, Xu X, Li H, et al (2011). Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol, 31, 2756-71.
34. Kim TS, Kim YB (1999). Correlation between expression of matrix metalloproteinas-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J Korean Med Sci, 14, 263-70.
35. Krajewska M, Wang HG, Krajewski S, et al (1997). Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res, 57, 1605-13.
36. Lau MT, Klausen C, Leung PC(2011). E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via b-catenin-Egr1-mediated PTEN expression. Oncogene, 30, 2753-66.
37. Lee Jr JT, Steelman LS, McCubrey JA (2004). Phosphatidylinositol 3?-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresi-stance in advanced prostate cancer cells. Cancer Res, 64, 8397-404.
38. Li DM, Sun H(1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res, 57, 2124-9.
39. Li J, Yen C, Liaw D, et al (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-7.
40. Lima EM, Araújo JJ, Harada ML,et al (2005). Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin Exp Med, 5, 129-32.
41. Li M, Sun H, Song L, et al (2012). Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett, 4,1213-8.
42. Li Y, Cui J, Zhang CH, et al (2013). High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma. Int J Med Sci, 10, 1689-97.
43. Li YL, Tian Z, Wu DY, Fu BY, Xin Y (2005). Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol, 11, 285-8.
44. Maehama T, Dixon JE (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid Second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem, 273, 13375-8.
45. Maehama T, Taylor GS, Dixon JE (2001). PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem, 70, 247-79.
46. Martelli AM, Evangelisti C, Chappell W, et al (2011). Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR Pathway. Leukemia, 25,1064-79.
47. Meng X, Wang Y, Zheng X, et al (2012). ShRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and Metastasis. Lung Cancer, 77, 24-30.
48. Moon SH, Kim DK, Cha Y, et al (2013). PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol, 42, 921-8.
49. Oki E, Baba H, Tokunaga E, et al (2005). Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer, 117, 376-80.
50. Oki E, Kakeji Y, Baba H, et al (2006). Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol, 21, 814-8.
51. Patel L, Pass I, Coxon P, et al (2001). Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol, 11,764-8.
52. Patel R, Gao M, Ahmad I, et al (2013). Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest, 123, 1157-75.
53. Rahdar M, Inoue T, Meyer T, et al (2009). phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. ProcNatl Acad Sci USA, 106, 480-5.
54. Romano C, Schepis C (2012). PTEN gene: a model for genetic diseases in dermatology. Sci World J, 2012, 252457.
55. Sakamaki J, Daitoku H, Ueno K, et al (2011). Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci USA, 108, 6085-90.
56. Sato K, Tamura G, Tsuchiya T, et al (2002). Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch, 440,160-5.
57. Schoof CR, Botelho EL, Izzotti A, dos Vasques LR (2012). MicroRNAs in cancer treatment and prognosis. Am J Cancer Res, 2, 414-33.
58. Schwartzbauer G, Robbins J (2001). The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem, 276, 35786-93.
59. Shen WH, Balajee AS, Wang J, et al (2007). Essential role for nuclear PTEN in Maintaining chromosomal integrity. Cell, 128, 157-70.
60. Song MS, Carracedo A, Salmena L, et al (2011). Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell, 144, 187-99.
61. Stambolic V, MacPherson D, Sas D, et al (2001). Regulation of PTEN transcription by p53. Mol Cell, 8, 317-25.
62. Steck PA, Pershouse MA, Jasser SA, et al (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15, 356-62.
63. Tamguney T, Stokoe D (2007). New insights into PTEN. J Cell Sci, 120, 4071-9.
64. Tamura M, Gu J, Matsumoto K, et al (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-7.
65. Tamura M, Gu J, Takino T, Yamada KM (1999). Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res, 59, 442-9.
66. Tian L, Fang YX, Xue JL, Chen JZ (2013). Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One, 8, e75885.
67. Torres J, Pulido R (2001). The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem, 276, 993-8.
68. Trotman LC, Wang X, Alimonti A, et al (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell, 128, 141-56.
69. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000). Phosphory-lation of the PTEN tail regulates protein stability and function. Mol Cell Biol, 20, 5010-8.
70. Virolle T, Adamson ED, Baron V, et al (2001). The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol, 3, 1124-8.
71. Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3, CD004064.
72. Waite KA, Eng C (2002). Protean PTEN: form and function. Am J Hum Genet, 70, 829-44.
73. Wang JY, Huang TJ, Chen FM, et al (2003). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch, 442, 437-43.
74. Wang X, Trotman LC, Koppie T, et al (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell, 128, 129-39.
75. Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YMM (2011). MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res, 42, 281-90.
76. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M (1999). PTEN genetransfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene, 18, 3936-43.
77. Xu JL, Wang ZW, Hu LM, et al (2012). Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Platinum-based Chemotherapy Response of Advanced Non-small Cell Lung Cancers in a Chinese Population. Asian Pacific J Cancer Prev, 13, 2157-62.
78. Yang E, Zha J, Jockel J, et al (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 80, 285-91.
79. Yang L, Kuang LG, Zheng HC, et al (2003). PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol, 9, 35-9.
80. Yang TS, Yang XH, Wang XD, et al (2013). MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int, 13, 68.
81. Yang Z, Yuan XG, Chen J, Lu NH (2012). Is NEDD4-1 a negative regulator of phosphatase and tensin homolog in gastric carcinogenesis? World J Gastroenterol, 18, 6345-8.
82. Yang Z, Yuan XG, Chen J, et al (2013). Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol, 37, 72-9.
83. Ye B, Jiang LL, Xu HT, Zhou DW, Li ZS (2012). Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol, 25, 627-36.
84. Yu BQ, Su LP, Li JF, et al (2012). microRNA expression signature of gastric cancer cells relative to normal gastric mucosa. Mol Med Rep, 6, 821-6.
85. Yu HG, Ai YW, Yu LL, et al (2008). Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer, 122, 433-43.
86. Zhang S, Huang WC, Li P, et al (2011). Combating trastuzmab resistance by targeting SRC, a common node down-stream of multiple resistance pathways. Nat Med, 17, 461-9.
87. Zhang X, Yan Z, Zhang J, et al (2011). Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients Following surgical resection. Ann Oncol, 22, 2257-66.
88. Zheng HC, Chen Y, Kuang LG, et al (2003). Expression of PTEN-encoding product in different stages of carcinogenesis and progression of gastric Carcinoma. ZhonghuaZhongliu Zazhi, 25, 13-6.
89. Zheng HC, Sun JM, Li XH, et al (2003). Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathol Int, 53, 659-66.